Travis Dalton Buys 15,380 Shares of Claritev (NYSE:CTEV) Stock

Claritev (NYSE:CTEV) CEO Travis Dalton bought 15,380 shares of the company’s stock in a transaction on Friday, February 27th. The shares were acquired at an average price of $13.00 per share, with a total value of $199,940.00. Following the transaction, the chief executive officer directly owned 24,952 shares in the company, valued at approximately $324,376. The trade was a 160.68% increase in their position. The purchase was disclosed in a legal filing with the SEC, which is available through this link.

Claritev Stock Up 17.1%

NYSE:CTEV opened at $16.90 on Wednesday. Claritev has a 12-month low of $12.04 and a 12-month high of $74.07. The stock’s fifty day simple moving average is $27.88 and its 200-day simple moving average is $45.93. The firm has a market capitalization of $279.02 million, a P/E ratio of -0.98 and a beta of 0.60.

Wall Street Analyst Weigh In

CTEV has been the subject of several analyst reports. Weiss Ratings restated a “sell (d-)” rating on shares of Claritev in a research report on Monday, December 29th. Citigroup reduced their price objective on shares of Claritev from $63.00 to $21.00 and set a “buy” rating on the stock in a research note on Wednesday, February 25th. UBS Group reaffirmed a “buy” rating on shares of Claritev in a research note on Tuesday, February 24th. Wells Fargo & Company set a $30.00 target price on shares of Claritev and gave the stock an “equal weight” rating in a report on Tuesday, February 24th. Finally, Guggenheim reissued a “buy” rating on shares of Claritev in a research report on Tuesday, February 24th. Three analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Hold” and an average price target of $29.67.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of the stock. H&F Corporate Investors VIII Ltd. acquired a new position in shares of Claritev in the third quarter valued at approximately $285,988,000. AustralianSuper Pty Ltd acquired a new stake in shares of Claritev during the third quarter worth $169,605,000. Arini Captial Management Ltd bought a new stake in Claritev in the 4th quarter valued at $64,291,000. Public Investment Fund bought a new stake in Claritev in the 3rd quarter valued at $68,009,000. Finally, Vanguard Group Inc. acquired a new position in Claritev in the 3rd quarter worth $27,483,000. Institutional investors own 87.15% of the company’s stock.

Claritev Company Profile

Claritev is a healthcare technology, data and insights company focused on improving affordability,  transparency and quality. Led by deeply experienced associates, data scientists, and innovators, Claritev provides tech-enabled solutions and services fueled by multiple data sources from over 40 years of claims repricing. Claritev utilizes world-class technology and AI solutions to power a robust enterprise platform that delivers meaningful insights to drive affordability in healthcare, brings price transparency and optimizes networks and benefits design.